QAI Labs Ltd. is a Delaware corporation headquartered in Sugar Land, Texas, building at the intersection of pharma business development, quantum hardware partnerships, and multi-specific antibody engineering — with collaborators across North America, Europe, and Asia-Pacific.
Dr. Daniel Feng is a drug developer and entrepreneur with a background in antibody engineering. He has worked at Medarex and Bristol-Myers Squibb, where he contributed to therapeutic antibody programs that advanced through Phase I/II clinical evaluation. At QAI Labs he leads overall company strategy, platform commercialization, and partnerships. The platform's quantum methods are validated on simulators today, with hardware access (IBM Quantum, Quantinuum) in progress. Dr. Feng brings the commercial and regulatory discipline of a seasoned pharma professional to the platform: every design claim is held to the evidentiary standard that a pharma diligence team would require, not a computational benchmark.
Dr. Xin Gao is a physician-scientist and co-inventor of the XFab multi-specific antibody design platform. The core XFab intellectual property — covering the module-based assembly methodology and multi-specific format engineering — is owned by a third-party licensor and licensed to QAI Labs (subject to the terms of that license), with patent assignments in progress; it forms the scientific foundation of the NOVA-3 Module Library and design workflow. (License structure available for review under NDA.) With a clinical background and direct experience advancing multi-specific antibody candidates through preclinical and early clinical development, Dr. Gao leads program strategy and platform architecture at QAI Labs. His approach to each program starts with the question a clinical development team would ask: what evidence would be required to justify moving this candidate forward?
Dr. Min Wang is a computational scientist and co-inventor of the XFab platform for quantum-augmented molecular simulation. The XFab computational methods — covering active-space quantum chemistry, hybrid classical-quantum optimization, and structure-based affinity prediction — are owned by a third-party licensor and licensed to QAI Labs (subject to the terms of that license), with patent assignments in progress; they underpin the NOVA-3 quantum compute layer. (License structure available for review under NDA.) At QAI Labs she architects the quantum AI stack: VQE active-space energy corrections and QAOA-based multi-specific assignment optimization — validated on simulators today, with the engineering interface ready for IBM Quantum / Quantinuum hardware once access is in place. Her discipline on the quantum question is explicit: the platform reports the hardware fraction of every job and makes no claim of demonstrated quantum advantage in ground-state chemistry, engaging with that open question honestly.
Our scientific advisory board will be announced alongside our first external program engagement. If you are a KOL in oncology or immuno-oncology and are interested in engaging, reach out at partner@qailabs.co.
Engineering, ML/structural biology, BD-APAC, regulatory affairs, and wet-lab operations. Plus we work with partner labs across North America, Europe, and Asia-Pacific for the wet-lab side of the data flywheel.